FEZ1/LZTS1 protein expression in ovarian cancer

Daniela Califano, Sandro Pignata, Carmela Pisano, Stefano Greggi, Giuseppe Laurelli, Nunzia Simona Losito, Alessandro Ottaiano, Adolfo Gallipoli, Rosa Pasquinelli, Veronica De Simone, Roberto Cirombella, Alfredo Fusco, Gennaro Chiappetta

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The FEZ1/LZTS1 (FEZ1) gene maps to chromosome 8p22 and is frequently altered in human cancer. FEZ1 has been proposed as a candidate tumour suppressor gene and its loss may contribute to tumour progression. We have analysed the expression of FEZ1 protein in tissues from ovarian carcinomas in relation to clinico-pathological variables, response to chemotherapy and disease-free and overall survival. FEZ1 status was assessed by immunohistochemistry. Cytoplasmic staining for FEZ1 protein was absent or drastically reduced in 38% of tumours. FEZ1 protein expression was not related to tumour grade, histotype, disease-free survival, or overall survival.Onthe contrary, it was significantly correlated with age and with FIGO stage of disease. This finding indicates that FEZ1 is involved in ovarian carcinogenesis. Moreover, loss of FEZ1 protein significantly predicted a complete treatment response in patients who received taxane-based chemotherapy. In conclusion, the reduction or loss of FEZ1 protein could be an aid to the clinical management of patients affected by ovarian carcinoma.

Original languageEnglish
Pages (from-to)382-386
Number of pages5
JournalJournal of Cellular Physiology
Volume222
Issue number2
DOIs
Publication statusPublished - Feb 2010

Fingerprint

Ovarian Neoplasms
Tumors
Chemotherapy
Proteins
Disease-Free Survival
Neoplasms
Genes
Carcinoma
Drug Therapy
Chromosomes
Tumor Suppressor Genes
Carcinogenesis
Immunohistochemistry
Tissue
Staining and Labeling
Survival
Therapeutics

ASJC Scopus subject areas

  • Cell Biology
  • Clinical Biochemistry
  • Physiology

Cite this

FEZ1/LZTS1 protein expression in ovarian cancer. / Califano, Daniela; Pignata, Sandro; Pisano, Carmela; Greggi, Stefano; Laurelli, Giuseppe; Losito, Nunzia Simona; Ottaiano, Alessandro; Gallipoli, Adolfo; Pasquinelli, Rosa; De Simone, Veronica; Cirombella, Roberto; Fusco, Alfredo; Chiappetta, Gennaro.

In: Journal of Cellular Physiology, Vol. 222, No. 2, 02.2010, p. 382-386.

Research output: Contribution to journalArticle

Califano, Daniela ; Pignata, Sandro ; Pisano, Carmela ; Greggi, Stefano ; Laurelli, Giuseppe ; Losito, Nunzia Simona ; Ottaiano, Alessandro ; Gallipoli, Adolfo ; Pasquinelli, Rosa ; De Simone, Veronica ; Cirombella, Roberto ; Fusco, Alfredo ; Chiappetta, Gennaro. / FEZ1/LZTS1 protein expression in ovarian cancer. In: Journal of Cellular Physiology. 2010 ; Vol. 222, No. 2. pp. 382-386.
@article{031553b2cce34782a0b083516de5048b,
title = "FEZ1/LZTS1 protein expression in ovarian cancer",
abstract = "The FEZ1/LZTS1 (FEZ1) gene maps to chromosome 8p22 and is frequently altered in human cancer. FEZ1 has been proposed as a candidate tumour suppressor gene and its loss may contribute to tumour progression. We have analysed the expression of FEZ1 protein in tissues from ovarian carcinomas in relation to clinico-pathological variables, response to chemotherapy and disease-free and overall survival. FEZ1 status was assessed by immunohistochemistry. Cytoplasmic staining for FEZ1 protein was absent or drastically reduced in 38{\%} of tumours. FEZ1 protein expression was not related to tumour grade, histotype, disease-free survival, or overall survival.Onthe contrary, it was significantly correlated with age and with FIGO stage of disease. This finding indicates that FEZ1 is involved in ovarian carcinogenesis. Moreover, loss of FEZ1 protein significantly predicted a complete treatment response in patients who received taxane-based chemotherapy. In conclusion, the reduction or loss of FEZ1 protein could be an aid to the clinical management of patients affected by ovarian carcinoma.",
author = "Daniela Califano and Sandro Pignata and Carmela Pisano and Stefano Greggi and Giuseppe Laurelli and Losito, {Nunzia Simona} and Alessandro Ottaiano and Adolfo Gallipoli and Rosa Pasquinelli and {De Simone}, Veronica and Roberto Cirombella and Alfredo Fusco and Gennaro Chiappetta",
year = "2010",
month = "2",
doi = "10.1002/jcp.21962",
language = "English",
volume = "222",
pages = "382--386",
journal = "Journal of cellular and comparative physiology",
issn = "0021-9541",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - FEZ1/LZTS1 protein expression in ovarian cancer

AU - Califano, Daniela

AU - Pignata, Sandro

AU - Pisano, Carmela

AU - Greggi, Stefano

AU - Laurelli, Giuseppe

AU - Losito, Nunzia Simona

AU - Ottaiano, Alessandro

AU - Gallipoli, Adolfo

AU - Pasquinelli, Rosa

AU - De Simone, Veronica

AU - Cirombella, Roberto

AU - Fusco, Alfredo

AU - Chiappetta, Gennaro

PY - 2010/2

Y1 - 2010/2

N2 - The FEZ1/LZTS1 (FEZ1) gene maps to chromosome 8p22 and is frequently altered in human cancer. FEZ1 has been proposed as a candidate tumour suppressor gene and its loss may contribute to tumour progression. We have analysed the expression of FEZ1 protein in tissues from ovarian carcinomas in relation to clinico-pathological variables, response to chemotherapy and disease-free and overall survival. FEZ1 status was assessed by immunohistochemistry. Cytoplasmic staining for FEZ1 protein was absent or drastically reduced in 38% of tumours. FEZ1 protein expression was not related to tumour grade, histotype, disease-free survival, or overall survival.Onthe contrary, it was significantly correlated with age and with FIGO stage of disease. This finding indicates that FEZ1 is involved in ovarian carcinogenesis. Moreover, loss of FEZ1 protein significantly predicted a complete treatment response in patients who received taxane-based chemotherapy. In conclusion, the reduction or loss of FEZ1 protein could be an aid to the clinical management of patients affected by ovarian carcinoma.

AB - The FEZ1/LZTS1 (FEZ1) gene maps to chromosome 8p22 and is frequently altered in human cancer. FEZ1 has been proposed as a candidate tumour suppressor gene and its loss may contribute to tumour progression. We have analysed the expression of FEZ1 protein in tissues from ovarian carcinomas in relation to clinico-pathological variables, response to chemotherapy and disease-free and overall survival. FEZ1 status was assessed by immunohistochemistry. Cytoplasmic staining for FEZ1 protein was absent or drastically reduced in 38% of tumours. FEZ1 protein expression was not related to tumour grade, histotype, disease-free survival, or overall survival.Onthe contrary, it was significantly correlated with age and with FIGO stage of disease. This finding indicates that FEZ1 is involved in ovarian carcinogenesis. Moreover, loss of FEZ1 protein significantly predicted a complete treatment response in patients who received taxane-based chemotherapy. In conclusion, the reduction or loss of FEZ1 protein could be an aid to the clinical management of patients affected by ovarian carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=73349110980&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73349110980&partnerID=8YFLogxK

U2 - 10.1002/jcp.21962

DO - 10.1002/jcp.21962

M3 - Article

VL - 222

SP - 382

EP - 386

JO - Journal of cellular and comparative physiology

JF - Journal of cellular and comparative physiology

SN - 0021-9541

IS - 2

ER -